BioSpecifics Technologies (BioSpecifics Technologies) Interest Coverage : N/A (As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BioSpecifics Technologies's Operating Income for the three months ended in Sep. 2020 was $6.51 Mil. BioSpecifics Technologies's Interest Expense for the three months ended in Sep. 2020 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. BioSpecifics Technologies Corp has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for BioSpecifics Technologies's Interest Coverage or its related term are showing as below:

BSTC's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioSpecifics Technologies Interest Coverage Historical Data

The historical data trend for BioSpecifics Technologies's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioSpecifics Technologies Interest Coverage Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Interest Coverage

Get a 7-Day Free Trial

No Debt

N/A

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Interest Coverage	Get a 7-Day Free Trial															No Debt	N/A	N/A	N/A	N/A

Competitive Comparison of BioSpecifics Technologies's Interest Coverage

For the Biotechnology subindustry, BioSpecifics Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioSpecifics Technologies's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Interest Coverage falls into.

BioSpecifics Technologies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioSpecifics Technologies's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as

Here, for the fiscal year that ended in Dec. 2019, BioSpecifics Technologies's Interest Expense was $0.00 Mil. Its Operating Income was $28.31 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.17 Mil.

GuruFocus does not calculate BioSpecifics Technologies's interest coverage with the available data.

BioSpecifics Technologies's Interest Coverage for the quarter that ended in Sep. 2020 is calculated as

Here, for the three months ended in Sep. 2020, BioSpecifics Technologies's Interest Expense was $0.00 Mil. Its Operating Income was $6.51 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.11 Mil.

GuruFocus does not calculate BioSpecifics Technologies's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

BioSpecifics Technologies (NAS:BSTC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

BioSpecifics Technologies Interest Coverage Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487